SHEEL: Safety of 6 Hours Feeding After Extracorporeal Shock Wave Lithotripsy of Pancreatic Stone

Sponsor
Changhai Hospital (Other)
Overall Status
Not yet recruiting
CT.gov ID
NCT05669573
Collaborator
(none)
216
1
2
6.9
31.2

Study Details

Study Description

Brief Summary

The purpose of this study is to evaluate the safety of eating 6 hours after Extracorporeal Shock Wave Lithotripsy (ESWL). At present, ESWL and Endoscopic Retrograde Cholangiopancreatography (ERCP) are the routine ways to treat pancreatic duct stones. For large stones (diameter > 5mm) , ESWL often needs to be performed many times. In clinical practice, fasting for 24 hours after surgery is often used, but long-term fasting brings strong discomfort to patients. However, the consensus for initiation timing of oral nutrition has not yet been established after ESWL. Thus, we design this trial to evaluate the safety of early feeding based on 6 hours parameter instead of the consensus definition.

Condition or Disease Intervention/Treatment Phase
  • Procedure: Early feeding group
  • Procedure: Standard fasting group
N/A

Detailed Description

In recent years, studies have shown that early recovery of enteral nutrition has significant benefits for patients. Early recovery of oral feeding and drinking as well as early oral supplementary nutrition after surgery can promote the recovery of intestinal motor function, help maintain intestinal mucosal function, prevent postoperative flora disorder and diarrhea, shorten postoperative hospital stay, and improve postoperative anxiety of patients.This study mainly evaluated the safety of feeding 6 hours after ESWL, including the risk of post-ESWL pancreatitis and other adverse events, as well as the length of hospital stay, medical expenses, pain, etc. This research conclusion is helpful to provide more scientific and reasonable fasting time for patients after ESWL, improve patient comfort, reduce the risk of adverse events, shorten hospital stay, save medical expenses, and guide clinical practice.

Study Design

Study Type:
Interventional
Anticipated Enrollment :
216 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
None (Open Label)
Primary Purpose:
Health Services Research
Official Title:
Safety of 6 Hours Feeding After Extracorporeal Shock Wave Lithotripsy of Pancreatic Stone: a Randomized Controlled Trial
Anticipated Study Start Date :
Jan 1, 2023
Anticipated Primary Completion Date :
May 31, 2023
Anticipated Study Completion Date :
Jul 31, 2023

Arms and Interventions

Arm Intervention/Treatment
Experimental: Early feeding group

Patients in the early diet group started oral intake 6 hours after ESWL of the day of procedure with a soft diet comprised 200 mL with 170 kilocalories. Observe closely until 24h, and then continue to fasting until the next ESWL/ERCP or change the diet to the general diet according to the actual clinical needs.

Procedure: Early feeding group
Patients in the early diet group started oral intake 6 hours after ESWL of the day of procedure with a soft diet comprised 200 mL with 170 kilocalories.

Active Comparator: Standard fasting group

Patients in the standard fasting group were fasted for 24 hours after the first ESWL operation, and close observation during this fasting period. After 24 hours, according to the actual clinical needs, continue to fast until the next ESWL/ERCP operation, or change the diet to a general diet.

Procedure: Standard fasting group
Patients in the standard fasting group were fasted for 24 hours after the first ESWL operation, and close observation during this fasting period.

Outcome Measures

Primary Outcome Measures

  1. the incidence of post-ESWL pancreatitis [within 24 hours after ESWL]

    A diagnosis of post-ESWL pancreatitis was thus made if two of three of the following criteria were met, in accordance with the revised Atlanta international consensus: pain consistent with pancreatitis; amylase or lipase of at least three times the upper normal limit within 24 h of the procedure; or characteristic findings on imaging.

Secondary Outcome Measures

  1. the severity of post-ESWL pancreatitis [within 24 hours after ESWL]

    stratified as mild, moderate, or severe, mainly on the basis of length of hospitalisation and need for invasive treatment

  2. the incidence of other post-ESWL complications [within 24 hours after ESWL]

    Other post ESWL complications includes bleeding, infection, steinstrasse, and perforation.

  3. the transient adverse events [within 24 hours after ESWL]

    Transient adverse events were defined as transient injuries caused by shock waves that required no medical intervention and did not prolong hospitalisation, including asymptomatic hyperamylasaemia, haematuria, and acute gastrointestinal mucosal injury (eg, haematemesis, melena, or haematochezia) caused by ESWL.

  4. abdominal pain relief rate [within 24 hours after ESWL]

    Use the Visual Analogue Scale (VAS). VAS can be calculated ranging from 0 (no pain) to 10 (severe pain).

  5. hunger relief rate [within 24 hours after ESWL]

    Use the Visual Analogue Scale (VAS). VAS can be calculated ranging from 0 (not hungry at all) to 10 (hungriest possible).

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years to 70 Years
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • Patients with chronic pancreatitis who completed ESWL.
Exclusion Criteria:
  • Readmitted to the hospital during enrollment of the study;

  • Cannot eat or rely on jejunal nutrition tube to give total parenteral nutrition for various reasons;

  • With acute pancreatitis, perforation, infection, bleeding, steinstrasse and other complications and other serious clinical adverse events within 6 hours after ESWL;

  • Suspected or confirmed malignancy

  • Pancreatic ascites;

  • Coagulation dysfunction;

  • Taking chemotherapy drugs and immunosuppressants for a long time;

  • Acute pancreatitis exacerbation or acute exacerbation of chronic pancreatitis (including biliary pancreatitis);

  • Pregnant or breastfeeding women;

  • Patients who refused to participate in the study.

Contacts and Locations

Locations

Site City State Country Postal Code
1 Changhai Hospital Shanghai China 200433

Sponsors and Collaborators

  • Changhai Hospital

Investigators

  • Principal Investigator: Liang-hao Hu, MD, Changhai Hospital

Study Documents (Full-Text)

None provided.

More Information

Publications

Responsible Party:
Zhaoshen Li, Professor, Changhai Hospital
ClinicalTrials.gov Identifier:
NCT05669573
Other Study ID Numbers:
  • SHEEL202210
First Posted:
Jan 3, 2023
Last Update Posted:
Jan 3, 2023
Last Verified:
Dec 1, 2022
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Additional relevant MeSH terms:

Study Results

No Results Posted as of Jan 3, 2023